Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer

Related Experiment Video

Updated: Jul 16, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Kunihiko Nakazawa1, Takahiro Nemoto, Tomoko Hata

  • 1Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Cancer
|February 24, 2007
PubMed
Abstract

Insights

A novel atelocollagen delivery system effectively releases ornithine decarboxylase (ODC) antisense oligonucleotides, inhibiting cancer cell growth. This method shows promise for sustained cancer treatment by targeting ODC in various human cancers.

Area of Science:

  • Oncology
  • Biotechnology
  • Drug Delivery

Background:

  • Ornithine decarboxylase (ODC) plays a crucial role in human tumor development and progression.
  • Antisense oligonucleotide (ASO) therapy is a promising cancer treatment, but effective in vivo delivery remains a challenge.
  • Atelocollagen offers a novel solution for sustained release of ODC ASOs.

Purpose of the Study:

  • To evaluate the efficacy of ODC ASOs delivered via atelocollagen for cancer treatment.
  • To assess the impact of this novel delivery system on cancer cell growth in vitro and in vivo.

Main Methods:

  • In vitro studies utilized cell counting to assess the effect of ODC ASOs in atelocollagen on gastrointestinal cancer (MKN45, COLO201) and rhabdomyosarcoma (RD) cell lines.
  • In vivo studies involved single administrations of ODC ASOs in atelocollagen via intratumoral, intramuscular, and intraperitoneal routes in tumor-bearing mice.
  • ODC activity and polyamine levels were measured to assess therapeutic impact.

Main Results:

  • ODC ASOs encapsulated in atelocollagen significantly inhibited the growth of MKN45, COLO201, and RD cancer cells in vitro.
  • A single administration of ODC ASOs in atelocollagen suppressed tumor growth in vivo for 35-42 days across all tested administration routes.
  • The treatment demonstrated sustained release and prolonged efficacy of ODC ASOs.

Conclusions:

  • The novel atelocollagen-based delivery system provides sustained release and prolonged efficacy of ODC ASOs.
  • This approach holds significant potential for the treatment of human cancers that overexpress ODC.
  • Further research into this ODC ASO delivery method could advance cancer therapeutics.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.